Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study

Journal:
The Lancet Oncology
Published:
DOI:
10.1016/s1470-2045(25)00287-6
Affiliations:
15
Authors:
17
Go to article
Institutions Authors Share
Jazz Pharmaceuticals PLC, United States of America (USA)
3.000000
 0.18
Princess Margaret Cancer Centre, U of T, Canada
1.000000
 0.06
Sarah Cannon Research Institute (SCRI), United States of America (USA)
1.000000
 0.06
Asan Medical Center (AMC), South Korea
1.000000
 0.06
Virginia Mason Medical Center (Virginia Mason), United States of America (USA)
1.000000
 0.06
Pusan National University Hospital (PNUH), South Korea
1.000000
 0.06
Seoul National University Bundang Hospital (SNUBH), South Korea
1.000000
 0.06
Memorial Sloan Kettering Cancer Center (MSKCC), United States of America (USA)
1.000000
 0.06
Fox Chase Cancer Center (FCCC), United States of America (USA)
1.000000
 0.06
Seoul National University Hospital (SNUH), South Korea
1.000000
 0.06
USC Norris Comprehensive Cancer Center, United States of America (USA)
1.000000
 0.06
NewYork-Presbyterian / Weill Cornell Medical Center, United States of America (USA)
1.000000
 0.06
Korea University Anam Hospital, South Korea
1.000000
 0.06
Yonsei Cancer Hospital, South Korea
1.000000
 0.06
The University of Texas MD Anderson Cancer Center, United States of America (USA)
1.000000
 0.06
Interested in Oncology and Carcinogenesis?